| Literature DB >> 30416055 |
Peter Valent1, Joanna N G Oude Elberink2, Aleksandra Gorska3, Magdalena Lange4, Roberta Zanotti5, Björn van Anrooij2, Massimiliano Bonifacio5, Patrizia Bonadonna6, Karoline V Gleixner7, Emir Hadzijusufovic8, Cecelia Perkins9, Karin Hartmann10, Anja Illerhaus11, Serena Merante12, Chiara Elena12, Khalid Shoumariyeh13, Nikolas von Bubnoff14, Roberta Parente15, Massimo Triggiani15, Juliana Schwaab16, Mohamad Jawhar16, Francesca Caroppo17, Anna Belloni Fortina17, Knut Brockow18, Rosemarie Greul19, Akif Selim Yavuz20, Michael Doubek21, Mattias Mattsson22, Hans Hagglund23, Jens Panse24, Vito Sabato25, Elisabeth Aberer26, Haifa Kathrin Al-Ali27, Marie-Anne Morren28, Judit Varkonyi29, Alexander Zink18, Marek Niedoszytko3, Dietger Niederwieser27, Luca Malcovati12, Andreas Reiter16, Vanessa Kennedy9, Jason Gotlib9, Olivier Lortholary30, Olivier Hermine31, Michel Arock32, Hanneke Kluin-Nelemans33, Wolfgang R Sperr7.
Abstract
Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future.Entities:
Keywords: Diagnostic criteria; Mastocytosis; Prognosis; Therapy; WHO classification
Mesh:
Year: 2018 PMID: 30416055 PMCID: PMC7115815 DOI: 10.1016/j.jaip.2018.09.024
Source DB: PubMed Journal: J Allergy Clin Immunol Pract